KR20150004416A - 면역 반응의 조절 - Google Patents

면역 반응의 조절 Download PDF

Info

Publication number
KR20150004416A
KR20150004416A KR20147033632A KR20147033632A KR20150004416A KR 20150004416 A KR20150004416 A KR 20150004416A KR 20147033632 A KR20147033632 A KR 20147033632A KR 20147033632 A KR20147033632 A KR 20147033632A KR 20150004416 A KR20150004416 A KR 20150004416A
Authority
KR
South Korea
Prior art keywords
sting
cells
dna
nucleic acid
trex1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20147033632A
Other languages
English (en)
Korean (ko)
Inventor
글렌 엔. 바버
Original Assignee
글렌 엔. 바버
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/460,408 external-priority patent/US20130039933A1/en
Application filed by 글렌 엔. 바버 filed Critical 글렌 엔. 바버
Publication of KR20150004416A publication Critical patent/KR20150004416A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR20147033632A 2012-04-30 2013-04-30 면역 반응의 조절 Ceased KR20150004416A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/460,408 US20130039933A1 (en) 2008-08-04 2012-04-30 Sting (stimulator of interferon genes), a regulator of innate immune responses
US13/460,408 2012-04-30
PCT/US2013/038840 WO2013166000A1 (en) 2012-04-30 2013-04-30 Modulating immune responses

Publications (1)

Publication Number Publication Date
KR20150004416A true KR20150004416A (ko) 2015-01-12

Family

ID=49514802

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147033632A Ceased KR20150004416A (ko) 2012-04-30 2013-04-30 면역 반응의 조절

Country Status (7)

Country Link
EP (1) EP2844756A4 (enExample)
JP (1) JP2015516989A (enExample)
KR (1) KR20150004416A (enExample)
CN (1) CN104540945A (enExample)
AU (1) AU2013256468A1 (enExample)
CA (1) CA2907616A1 (enExample)
WO (1) WO2013166000A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
SG11201502796RA (en) 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
JP2016506408A (ja) 2012-12-19 2016-03-03 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
CN105377867B (zh) 2013-05-03 2019-11-12 加利福尼亚大学董事会 I型干扰素的环状二核苷酸诱导
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
TWI706958B (zh) 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド
CN106540260A (zh) * 2015-12-09 2017-03-29 聊城市奥润生物医药科技有限公司 干扰素基因刺激蛋白（sting）激动剂在抗阿尔兹海默症中的应用
IL280430B2 (en) 2016-03-18 2023-11-01 Univ Texas Cyclic dinucleotide compounds and methods of use
CN106539757A (zh) * 2016-03-20 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP-脂质体在抗肿瘤中的应用
SG10201900628RA (en) 2016-04-07 2019-02-27 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
CN106667914B (zh) * 2017-03-13 2022-02-01 杭州星鳌生物科技有限公司 靶向脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用
AU2018344902B2 (en) 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
CA3078309A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Methods for administering sting agonists
US11377440B2 (en) 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
CN112351778B (zh) 2018-06-28 2023-04-04 江苏恒瑞医药股份有限公司 稠合三环杂环类化合物及其治疗用途
TW202104214A (zh) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021119753A1 (en) 2019-12-18 2021-06-24 Ctxt Pty Limited Compounds
AU2020405068A1 (en) 2019-12-18 2022-07-07 Stinginn Llc Substituted 1,2, 4-triazoles and methods of use
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
WO2025262266A1 (en) 2024-06-21 2025-12-26 Institut National de la Santé et de la Recherche Médicale Methods of determining the clinical phenotype of patients suffering from hidradenitis suppurativa

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2324044A4 (en) * 2008-08-04 2012-04-25 Univ Miami STING (STIMULATOR OF INTERFERON GENES) AS A REGULATOR OF BORROWING IMMUNE REACTIONS

Also Published As

Publication number Publication date
CA2907616A1 (en) 2013-11-07
JP2015516989A (ja) 2015-06-18
CN104540945A (zh) 2015-04-22
AU2013256468A1 (en) 2014-12-04
WO2013166000A1 (en) 2013-11-07
EP2844756A4 (en) 2016-02-24
EP2844756A1 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
US20200392492A1 (en) Modulating Immune Responses
AU2013256468A1 (en) Modulating immune responses
Fox et al. p53 and ATF4 mediate distinct and additive pathways to skeletal muscle atrophy during limb immobilization
JP7503558B2 (ja) 加齢関連炎症および障害を治療する、予防するまたは逆転させるための組成物および方法
Greco et al. Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy
Zhang et al. Sirtuin 6 inhibits myofibroblast differentiation via inactivating transforming growth factor‐β1/Smad2 and nuclear factor‐κB signaling pathways in human fetal lung fibroblasts
Kavazis et al. Effects of short-term endurance exercise training on acute doxorubicin-induced FoxO transcription in cardiac and skeletal muscle
Chen et al. Stat5-dependent cardioprotection in late remote ischaemia preconditioning
US9814741B2 (en) Methods relating to DNA-sensing pathway related conditions
Li et al. Wortmannin reduces metastasis and angiogenesis of human breast cancer cells via nuclear factor-κB-dependent matrix metalloproteinase-9 and interleukin-8 pathways
Tao et al. KPNA2 interacts with P65 to modulate catabolic events in osteoarthritis
Furrer et al. Absent in Melanoma 2 (AIM2) limits pro-inflammatory cytokine transcription in cardiomyocytes by inhibiting STAT1 phosphorylation
US9845471B2 (en) Compositions and methods for treating pancreatic cancer
Liu et al. POLR2A blocks osteoclastic bone resorption and protects against osteoporosis by interacting with CREB1
Levesque et al. Inflamed endothelial cells express S1PR1 inhibitor CD69 to induce vascular leak
Araujo et al. Prostatic acid phosphatase is the main acid phosphatase with 5′-ectonucleotidase activity in the male mouse saliva and regulates salivation
Suzuki et al. Manipulating histone acetylation leads to antitumor effects in hemangiosarcoma cells
Tokumoto et al. Neurotensin receptor 1 is a new therapeutic target for human undifferentiated pleomorphic sarcoma growth
WO2022137964A1 (ja) 軟骨・骨・関節疾患の予防または治療用医薬組成物および軟骨・骨・関節疾患の予防または治療用薬剤のスクリーニング方法
Samakkarnthai et al. In vitro and in vivo effects of zoledronate on senescence and senescence-associated secretory phenotype markers
Tang et al. p53 peptide prevents LITAF-induced TNF-alpha-mediated mouse lung lesions and endotoxic shock
Ke et al. Cilostazol attenuates ovariectomy-induced bone loss by inhibiting osteoclastogenesis
JP6659250B2 (ja) 癌の検査方法、癌細胞増殖阻害剤、抗癌剤及び抗癌剤のスクリーニング方法
JP2018177658A (ja) 去勢抵抗性前立腺癌の治療
RU2812903C2 (ru) Композиции и способы лечения, предотвращения и обращения связанного с возрастом воспаления и расстройств

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141128

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180424

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190718

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190926

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190718

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I